Neovascular (wet) age-related macular degeneration (AMD). Macular edema following retinal vein occlusion (RVO). Diabetic macular edema (DME).
Give by intravitreal inj. AMD: 0.5mg once a month (approx. 28 days); or 0.5mg every 3 months after the first 4 injections if monthly is not feasible (less effective). RVO: 0.5mg once a month (approx. 28 days). DME: 0.3mg once a month (approx. 28 days).
Recombinant humanized IgG1 kappa isotype monoclonal antibody fragment.
Ocular or periocular infections.
Monitor intraocular pressure prior to and 30 minutes after inj. Monitor for perfusion of optic nerve and for infection following the inj (endophthalmitis and retinal detachments possible). Pregnancy (Cat.C). Nursing mothers.
Conjunctival hemorrhage, eye pain, vitreous floaters, increased intraocular pressure, intraocular inflammation; rare: arterial thromboembolic events.
Single-use vial—1 (w. supplies)